YAP silencing in MCF-7 breast cancer cell line stabilizes wild-type p53 in response to cisplatin treatment, while this silencing in p53 null SAOS2 osteosarcoma cells promotes cell cycle progression but increases sensitivity to DNA damage by cisplatin (Ferraiuolo et al., 2018). The gene discussed is TP53; the disease is breast carcinoma.